Form 8-K - Current report:
SEC Accession No. 0001628280-23-002417
Filing Date
2023-02-06
Accepted
2023-02-06 16:02:57
Documents
14
Period of Report
2023-02-06
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20230206.htm   iXBRL 8-K 38452
2 EX-99.1 arwr-20230206x8kex9911.htm EX-99.1 68677
6 ghvnqo5ppwcq000001a.jpg GRAPHIC 49974
  Complete submission text file 0001628280-23-002417.txt   326827

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20230206.xsd EX-101.SCH 1929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20230206_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20230206_pre.xml EX-101.PRE 13064
8 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20230206_htm.xml XML 12133
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 23590653
SIC: 2834 Pharmaceutical Preparations